Urologic imaging for localized prostate cancer in 2007.

Increasing numbers of systematic random biopsies have virtually replaced urologic imaging as a detection and staging tool in prostate cancer. TRUS as the most commonly utilized urologic imaging is now mainly utilized to guide the biopsy needle into the correct anatomical or topographic region of the prostate. But even multiple systematic random biopsies have been shown to overlook a large number of clinically significant carcinoma. This fact has led to a dramatic increase in the number of biopsies taken in the detection of localized prostate cancer. There are some centers where 6, 10, 12, even up to 143 biopsies are taken in one sitting. This increasingly invasive and heterogeneous strategy underlines the need for an improvement in diagnostic imaging. New modalities and innovative techniques are currently being investigated in order to identify prostate cancer more accurately. The purpose of this paper is to review innovative urologic imaging techniques to identify emerging modalities that may be beneficial in the management of prostate cancer. Enhanced transrectal ultrasonography modalities, including ultrasound contrast agents, color and power doppler, elastography and computerized (C)-TRUS with artificial neural network analysis (ANNA) promise benefits in comparison to standard gray-scale ultrasonography to accurately target and diagnose prostate cancer.